Rx (Prescription Medicine)
USD $ 333.00
Ontramab 440mg 注射液是一种靶向疗法，用于治疗某些类型的癌症。其活性成分Ontramab是一种单克隆抗体，专门设计用于靶向并抑制癌细胞，从而减缓或停止其生长。该药物通过干扰癌细胞生存与增殖所依赖的特定蛋白质或通路起作用。Ontramab通常以静脉注射方式在医疗专业人员的监督下使用。它适用于经肿瘤科医生确定的特定癌症类型。剂量和给药频率将根据您的个体情况、癌症的类型和阶段以及对治疗的反应进行个体化处方。常见不良反应可能包括疲劳、恶心、腹泻以及输液反应。在开始使用Ontramab之前，务必与医生讨论您既往的疾病史和正在服用的其他药物。请按照生产厂家的说明进行储存，通常需置于室温并避光保存。
| Molecule | |
|---|---|
| Strength | |
| Pack Quantity | |
| Medicine Form | |
| Medicine Type | |
| Rx Status | |
| Country Of Origin | |
| Packaging Type | |
| Brand Name |
其他品牌的 Trastuzumab 440 mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
